DOI:
10.1055/s-00000094
Zeitschrift für Gastroenterologie
LinksClose Window
References
Thuss-Patience PC. et al.
Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – a randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO).
Eur J Cancer 2011;
47: 2306-2314
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.